This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Is ADMA Poised for Margin Growth and Supply Expansion in 2026?
by Ekta Bagri
ADMA rides on margin gains, supply deals, and IVIG shift into 2026, but valuation and recent stock decline add complexity for investors.
GRFSNegative Net Change ADMANegative Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Battle of Big Pharma: Is AbbVie Stock Pulling Ahead of Pfizer?
by Kinjel Shah
ABBV edges out PFE as Skyrizi and Rinvoq fuel strong growth, offsetting Humira losses and positioning the drugmaker for sustained expansion.
PFEPositive Net Change ABBVPositive Net Change
biotechs pharmaceuticals
BDTX and Brain Metastases: Why CNS Activity Could Matter in 2026
by Ekta Bagri
BDTX spotlights silevertinib's 86% CNS response in NSCLC, with 2026 durability data and a glioblastoma push shaping its brain-metastasis strategy.
BDTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Black Diamond Stock: Weighing Catalysts vs. Concentration
by Ekta Bagri
BDTX hinges on silevertinib's mutation breadth and CNS activity, with 2026 data, cash runway, and partnership moves set to shape its high-risk, high-reward path.
AZNNegative Net Change JNJPositive Net Change BDTXPositive Net Change
biotechnology biotechs pharmaceuticals
Does Cobenfy Have the Potential to Become a Top Drug for BMY?
by Ekta Bagri
BMY's Cobenfy gains traction with $155M in 2025 sales, outpacing peers and showing strong uptake as Bristol Myers eyes new indications and growth.
BMYPositive Net Change ABBVPositive Net Change RVPHPositive Net Change
biotechnology biotechs medical pharmaceuticals
BDTX: What Silevertinib Data Say About EGFR NSCLC Upside
by Ekta Bagri
BDTX bets on silevertinib's broad EGFR mutation reach and CNS activity, but with no approved products, upcoming 2026 data and partnerships are pivotal.
AZNNegative Net Change JNJPositive Net Change BDTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Gilead Expands Oncology Pipeline With $5B Tubulis Deal
by Zacks Equity Research
Gilead's $5B Tubulis deal expands its ADC pipeline, boosting oncology ambitions as the company accelerates strategic acquisitions beyond HIV.
BIIBPositive Net Change LLYPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
ACIU Stock Rallies 16.3% in a Week: Here's What You Need to Know
by Zacks Equity Research
AC Immune stock gains after expansion of its agreement with LLY, adding next-generation Tau Morphomer candidates and boosting long-term Alzheimer's strategy.
LLYPositive Net Change ACIUNegative Net Change INDVPositive Net Change
biotechs
Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why
by Zacks Equity Research
SLNO shares surge as Neurocrine inks $2.9B cash deal to acquire it at $53 a share, adding Vykat XR and expanding its rare disease and endocrinology portfolio.
NBIXPositive Net Change INDVPositive Net Change
biotechs
Insmed Ends Brinsupri Development in Skin Disease Post Study Failure
by Zacks Equity Research
INSM scraps Brinsupri for HS after phase IIb failure, with placebo outperforming treatment despite no safety issues.
INSMPositive Net Change ANIPPositive Net Change
biotechs medical